Organized by: Hoffmann-La Roche Ltd.In 2016, an estimated 747,000 Canadians were living with Alzheimer’s Disease (AD) and related dementias. It is estimated that by 2030, 1.4 million Canadians will have AD or related dementias, an increase of 66 percent. By 2050, that number will increase to 2.8 million. As in other major markets, this rapidly increasing prevalence of people with AD and dementia is a significant concern to policymakers who are exploring how they can best support patients with AD and related dementia and their loved ones.
Recognizing the significant need and their commitment to improving the lives of Canadians with dementia, the Government of Canada announced in May 2018 that it was moving forward with a National Dementia Strategy. The Strategy will consider the experience of those living with dementia and will build on existing working being undertaken across Canada in this area. The Strategy poses a unique opportunity to define what is required from a healthcare system readiness perspective.
The objective of the panel will be to explore the current work being undertaken by the Government of Canada to improve the regulatory and healthcare environment in order to bring innovative therapies into the hands of patients. The panel discussion is meant to ignite public policy discourse related to:
- Current state of affairs in Canada and what is required from a healthcare readiness perspective in order to positive impact the lives of patient living with AD and their caregivers
- Understand the current regulatory and market access decision making process and the gaps that exist in bringing innovative diagnostics and therapies to market in the area of Alzheimer’s Disease
- Existing healthcare system gaps and existing opportunities to bridge those gaps
